Avidity Partners Management LP I Mab Transaction History

Avidity Partners Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $20.6 Million - $33.8 Million	-454,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $15.7 Million - $23.2 Million	-275,000 Reduced 37.72%	454,000 $32.9 Million
Q2 2021 Aug 16, 2021	SELL	$47.86 - $83.95 $28.7 Million - $50.4 Million	-600,000 Reduced 45.15%	729,000 $61.2 Million
Q1 2021 May 17, 2021	SELL	$44.38 - $63.97 $11.6 Million - $16.8 Million	-262,000 Reduced 16.47%	1,329,000 $64.4 Million
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $8.27 Million - $11.8 Million	251,000 Added 18.73%	1,591,000 $75 Million
Q3 2020 Nov 16, 2020	BUY	$27.46 - $47.03 $36.8 Million - $63 Million	1,340,000 New	1,340,000 $63 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.